Serum biomarkers in patients with mesothelioma and pleural plaques and healthy subjects exposed to naturally occurring asbestos

Lung

Volumn 192, Issue 1, 2014, Pages 197-203

  Bayram, Mehmet ^a   Dongel, Isa ^b   Akbaş, Ali ^c   Benli, Ismail ^c   Akkoyunlu, Muhammed Emin ^a   Bakan, Nur Dilek ^d  

^a BEZMIALEM VAKIF UNIVERSITY   (Turkey)

^b SULEYMAN DEMIREL UNIVERSITY   (Turkey)

^c GAZIOSMANPASA UNIVERSITY   (Turkey)

^d Yedikule Teaching Hospital for Pulmonology and Thoracic Surgery   (Turkey)

Author keywords

Asbestos exposure; Mesothelin; Mesothelioma; Osteopontin

Indexed keywords

AGED; AREA UNDER CURVE; ASBESTOS; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; DIAGNOSIS, DIFFERENTIAL; GPI-LINKED PROTEINS; HUMANS; INHALATION EXPOSURE; LINEAR MODELS; MESOTHELIOMA; MIDDLE AGED; OSTEOPONTIN; PLEURA; PLEURAL NEOPLASMS; PREDICTIVE VALUE OF TESTS; RISK FACTORS; ROC CURVE; SMOKING; TUMOR MARKERS, BIOLOGICAL; TURKEY;

EID: 84894065827     PISSN: 03412040     EISSN: 14321750     Source Type: Journal    
DOI: 10.1007/s00408-013-9526-9     Document Type: Article

References (40)

1. Sugarbaker DJ, Flores RM, Jaklitsch MT et al (1999) Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J Thorac Cardiovasc Surg 117:54-63 discussion 63-55
2. Zellos L, Christiani DC (2004) Epidemiology, biologic behavior, and natural history of mesothelioma. Thorac Surg Clin 14:469-477, viii
3. Vogelzang NJ, Rusthoven JJ, Symanowski J et al (2003) Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21:2636-2644
4. Pantazopoulos I, Boura P, Xanthos T et al (2013) Effectiveness of mesothelin family proteins and osteopontin for malignant mesothelioma. Eur Respir J 41:706-715
5. Hassan R, Remaley AT, Sampson ML et al (2006) Detection and quantitation of serum mesothelin, a tumor marker for patients with mesothelioma and ovarian cancer. Clin Cancer Res 12:447-453
6. Beyer HL, Geschwindt RD, Glover CL et al (2007) MESOMARK: a potential test for malignant pleural mesothelioma. Clin Chem 53:666-672
7. Robinson BW, Creaney J, Lake R et al (2003) Mesothelin-family proteins and diagnosis of mesothelioma. Lancet 362:1612-1616
8. Fedarko NS, Jain A, Karadag A et al (2001) Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer. Clin Cancer Res 7:4060-4066
9. Pass HI, Lott D, Lonardo F et al (2005) Asbestos exposure, pleural mesothelioma, and serum osteopontin levels. N Engl J Med 353:1564-1573
10. Grigoriu BD, Scherpereel A, Devos P et al (2007) Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment. Clin Cancer Res 13:2928-2935
11. Park EK, Thomas PS, Johnson AR et al (2009) Osteopontin levels in an asbestos-exposed population. Clin Cancer Res 15:1362-1366
12. Myers R (2012) Asbestos-related pleural disease. Curr Opin Pulm Med 18:377-381
13. Bayram M, Dongel I, Bakan ND et al (2013) High risk of malignant mesothelioma and pleural plaques in subjects born close to ophiolites. Chest 143:164-171
14. Baumann F, Maurizot P, Mangeas M et al (2011) Pleural mesothelioma in New Caledonia: associations with environmental risk factors. Environ Health Perspect 119:695-700
15. Rey F, Viallat JR, Boutin C et al (1993) Environmental mesotheliomas in northeast Corsica. Rev Mal Respir 10:339-345
16. McConnochie K, Simonato L, Mavrides P et al (1989) Mesothelioma in Cyprus. IARC Sci Publ 411-419
17. Manda-Stachouli C, Dalavanga Y, Daskalopoulos G et al (2004) Decreasing prevalence of pleural calcifications among Metsovites with nonoccupational asbestos exposure. Chest 126:617-621
18. Magnani C, Dalmasso P, Biggeri A et al (2001) Increased risk of malignant mesothelioma of the pleura after residential or domestic exposure to asbestos: a case-control study in Casale Monferrato, Italy. Environ Health Perspect 109:915-919
19. Pan XL, Day HW, Wang W et al (2005) Residential proximity to naturally occurring asbestos and mesothelioma risk in California. Am J Respir Crit Care Med 172:1019-1025
20. Orenstein MR, Schenker MB (2000) Environmental asbestos exposure and mesothelioma. Curr Opin Pulm Med 6:371-377
21. Baris YI, Bilir N, Artvinli M et al (1988) An epidemiological study in an Anatolian village environmentally exposed to tremolite asbestos. Br J Ind Med 45:838-840
22. Case BW, Abraham JL, Meeker G et al (2011) Applying definitions of "asbestos" to environmental and "low-dose" exposure levels and health effects, particularly malignant mesothelioma. J Toxicol Environ Health B Crit Rev 14:3-39
23. Bianchi C, Giarelli L, Grandi G et al (1997) Latency periods in asbestos-related mesothelioma of the pleura. Eur J Cancer Prev 6:162-166
24. Berk S, Yalcin H, Dogan OT et al (2013) The assessment of the malignant mesothelioma cases and environmental asbestos exposure in Sivas province. Environ Geochem Health, Turkey
25. Dumortier P, Coplu L, de Maertelaer V et al (1998) Assessment of environmental asbestos exposure in Turkey by bronchoalveolar lavage. Am J Respir Crit Care Med 158:1815-1824
26. Dongel I, Bayram M, Bakan ND et al (2013) Is living close to ophiolites related to asbestos related diseases? Cross-sectional study. Respir Med 107:870-874
27. Creaney J, van Bruggen I, Hof M et al (2007) Combined CA125 and mesothelin levels for the diagnosis of malignant mesothelioma. Chest 132:1239-1246
28. Rodriguez Portal JA, Rodriguez Becerra E, Rodriguez Rodriguez D et al (2009) Serum levels of soluble mesothelin-related peptides in malignant and nonmalignant asbestos-related pleural disease: relation with past asbestos exposure. Cancer Epidemiol Biomarkers Prev 18:646-650
29. Scherpereel A, Grigoriu B, Conti M et al (2006) Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma. Am J Respir Crit Care Med 173:1155-1160
30. Cristaudo A, Bonotti A, Simonini S et al (2011) Combined serum mesothelin and plasma osteopontin measurements in malignant pleural mesothelioma. J Thorac Oncol 6:1587-1593
31. Gube M, Taeger D, Weber DG et al (2011) Performance of biomarkers SMRP, CA125, and CYFRA 21-1 as potential tumor markers for malignant mesothelioma and lung cancer in a cohort of workers formerly exposed to asbestos. Arch Toxicol 85:185-192
32. Hollevoet K, Nackaerts K, Thimpont J et al (2010) Diagnostic performance of soluble mesothelin and megakaryocyte potentiating factor in mesothelioma. Am J Respir Crit Care Med 181:620-625
33. Brims FJ, Lee YC, Creaney J (2013) The continual search for ideal biomarkers for mesothelioma: the hurdles. J Thorac Dis 5:364-366
34. Davies HE, Sadler RS, Bielsa S et al (2009) Clinical impact and reliability of pleural fluid mesothelin in undiagnosed pleural effusions. Am J Respir Crit Care Med 180:437-444
35. Amati M, Tomasetti M, Scartozzi M et al (2008) Profiling tumor-associated markers for early detection of malignant mesothelioma: an epidemiologic study. Cancer Epidemiol Biomarkers Prev 17:163-170
36. Shiomi K, Shiomi S, Ishinaga Y et al (2011) Impact of renal failure on the tumor markers of mesothelioma, N-ERC/mesothelin and osteopontin. Anticancer Res 31:1427-1430
37. Lowe KA, Shah C, Wallace E et al (2008) Effects of personal characteristics on serum CA125, mesothelin, and HE4 levels in healthy postmenopausal women at high-risk for ovarian cancer. Cancer Epidemiol Biomarkers Prev 17:2480-2487
38. Hollevoet K, Bernard D, De Geeter F et al (2009) Glomerular filtration rate is a confounder for the measurement of soluble mesothelin in serum. Clin Chem 55:1431-1433
39. Samitas K, Zervas E, Xanthou G et al (2013) Osteopontin is increased in the bronchoalveolar lavage fluid and bronchial tissue of smoking asthmatics. Cytokine 61:713-715
40. Creaney J, Yeoman D, Musk AW et al (2011) Plasma versus serum levels of osteopontin and mesothelin in patients with malignant mesothelioma-which is best? Lung Cancer 74:55-60